Autoimmune Diseases  >>  tabalumab (LY2127399)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tabalumab (LY2127399) / Eli Lilly
NCT01253226: A Study for Japanese Participants With Rheumatoid Arthritis (RA)

Completed
1
32
Japan
LY2127399 (Tabalumab), LY2127399, Tabalumab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis
08/11
08/11
NCT01253291: A Study of Japanese Rheumatoid Arthritis Participants

Completed
1
26
Japan
LY2127399, tabalumab
Eli Lilly and Company
Rheumatoid Arthritis
09/13
03/14

Download Options